We had an early Christmas with our team's latest work out in @BloodJournal. We investigated the benefit patients derive from Lenalidomide Maintenance in context of tumour genetics. ashpublications.org/blood/article-… Our aim was to interrogate clinically accessible markers that can support care discussions. The Len Maintenance registration trials included limited genetics. We investigated 556 patients with extended genetics randomized post ASCT to Len Maint or Observation in #MyelomaXI

Just as there is notably wider interest in chr1q abnormalities in myeloma now than when our data was published: here again a link to the excellent work chr1q copy number evolution and its clinical impact from James Croft on #UKMRA #MyelomaXI trial nature.com/articles/s4137… By investigating new copy number aberrations detected at relapse in 179 matched presentation-relapse tumours from #MyelomaXI, James discovered newly detected 1q aberrations to be most frequent, followed by del13q and del17p. As previous tweet shows, with equal adverse OS.